share_log

Prometheus Biosciences Analyst Ratings

Prometheus Biosciences Analyst Ratings

普羅米修斯生物科學分析師評級
Benzinga Analyst Ratings ·  2023/01/31 09:23
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/31/2023 25.47% Goldman Sachs $117 → $144 Maintains Buy
12/08/2022 23.73% Credit Suisse $59 → $142 Maintains Outperform
12/08/2022 57.71% BTIG $74 → $181 Maintains Buy
12/08/2022 8.91% Oppenheimer $61 → $125 Maintains Outperform
12/08/2022 -3.28% RBC Capital $66 → $111 Maintains Outperform
11/01/2022 -52.08% Stifel $50 → $55 Maintains Buy
10/04/2022 -43.36% Oppenheimer $50 → $65 Maintains Outperform
10/04/2022 -42.49% RBC Capital $61 → $66 Maintains Outperform
10/03/2022 -35.52% BTIG $62 → $74 Maintains Buy
08/29/2022 -41.62% Piper Sandler $53 → $67 Maintains Overweight
08/29/2022 -38.14% Wells Fargo $51 → $71 Maintains Overweight
08/12/2022 -48.59% Credit Suisse $52 → $59 Maintains Outperform
08/12/2022 -47.72% SVB Leerink $55 → $60 Maintains Outperform
07/20/2022 -55.56% Goldman Sachs → $51 Initiates Coverage On → Buy
06/10/2022 -53.82% Piper Sandler → $53 Initiates Coverage On → Overweight
05/13/2022 -60.79% RBC Capital $46 → $45 Maintains Outperform
05/13/2022 -55.56% Wells Fargo $53 → $51 Maintains Overweight
03/10/2022 -54.69% Credit Suisse $50 → $52 Maintains Outperform
03/10/2022 -53.82% Wells Fargo $42 → $53 Maintains Overweight
03/10/2022 -52.08% SVB Leerink $47 → $55 Maintains Outperform
02/11/2022 -45.98% BTIG → $62 Initiates Coverage On → Buy
12/13/2021 -59.92% RBC Capital → $46 Initiates Coverage On → Outperform
12/08/2021 -63.41% Wells Fargo → $42 Initiates Coverage On → Overweight
12/08/2021 -56.43% Oppenheimer $35 → $50 Upgrades Perform → Outperform
12/08/2021 -59.05% SVB Leerink $43 → $47 Maintains Outperform
11/15/2021 — Oppenheimer Downgrades Outperform → Perform
11/15/2021 -62.53% SVB Leerink $34 → $43 Maintains Outperform
10/05/2021 -69.5% Oppenheimer → $35 Initiates Coverage On → Outperform
04/06/2021 -65.15% Guggenheim → $40 Initiates Coverage On → Buy
04/06/2021 -78.22% Stifel → $25 Initiates Coverage On → Buy
04/06/2021 -70.38% SVB Leerink → $34 Initiates Coverage On → Outperform
04/06/2021 -73.86% Credit Suisse → $30 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
01/31/2023 25.47% 高盛 $117 → $144 維護 買
12/08/2022 23.73% 瑞士信貸 $59 → $142 維護 跑贏大盤
12/08/2022 57.71% BTIG $74 → $181 維護 買
12/08/2022 8.91% 奧本海默 $61 → $125 維護 跑贏大盤
12/08/2022 -3.28% 加拿大皇家銀行資本 $66 → $111 維護 跑贏大盤
11/01/2022 -52.08% Stifel $50 → $55 維護 買
10/04/2022 -43.36% 奧本海默 $50 → $65 維護 跑贏大盤
10/04/2022 -42.49% 加拿大皇家銀行資本 $61 → $66 維護 跑贏大盤
10/03/2022 -35.52% BTIG $62 → $74 維護 買
08/29/2022 -41.62% 派珀·桑德勒 $53 → $67 維護 超重
08/29/2022 -38.14% 富國銀行 $51 → $71 維護 超重
08/12/2022 -48.59% 瑞士信貸 $52 → $59 維護 跑贏大盤
08/12/2022 -47.72% SVB Leerink $55 → $60 維護 跑贏大盤
07/20/2022 -55.56% 高盛 → $51 開始承保 →購買
06/10/2022 -53.82% 派珀·桑德勒 → $53 開始承保 →超重
05/13/2022 -60.79% 加拿大皇家銀行資本 $46 → $45 維護 跑贏大盤
05/13/2022 -55.56% 富國銀行 $53 → $51 維護 超重
03/10/2022 -54.69% 瑞士信貸 $50 → $52 維護 跑贏大盤
03/10/2022 -53.82% 富國銀行 $42 → $53 維護 超重
03/10/2022 -52.08% SVB Leerink $47 → $55 維護 跑贏大盤
02/11/2022 -45.98% BTIG → $62 開始承保 →購買
12/13/2021 -59.92% 加拿大皇家銀行資本 → $46 開始承保 →跑贏大盤
12/08/2021 -63.41% 富國銀行 → $42 開始承保 →超重
12/08/2021 -56.43% 奧本海默 $35 → $50 升級 →表現強於大盤
12/08/2021 -59.05% SVB Leerink $43 → $47 維護 跑贏大盤
11/15/2021 — 奧本海默 評級下調 超越→表現
11/15/2021 -62.53% SVB Leerink $34 → $43 維護 跑贏大盤
10/05/2021 -69.5% 奧本海默 → $35 開始承保 →跑贏大盤
04/06/2021 -65.15% 古根海姆 → $40 開始承保 →購買
04/06/2021 -78.22% Stifel → $25 開始承保 →購買
04/06/2021 -70.38% SVB Leerink → $34 開始承保 →跑贏大盤
04/06/2021 -73.86% 瑞士信貸 → $30 開始承保 →跑贏大盤

What is the target price for Prometheus Biosciences (RXDX)?

普羅米修斯生物科學公司(RXDX)的目標價是多少？

The latest price target for Prometheus Biosciences (NASDAQ: RXDX) was reported by Goldman Sachs on January 31, 2023. The analyst firm set a price target for $144.00 expecting RXDX to rise to within 12 months (a possible 25.47% upside). 21 analyst firms have reported ratings in the last year.

高盛於2023年1月31日報道了普羅米修斯生物科學公司(納斯達克：RXDX)的最新目標價。這家分析公司將目標價定為144.00美元，預計RXDX將在12個月內上漲至25.47%(可能上漲25.47%)。去年有21家分析公司公佈了評級。

What is the most recent analyst rating for Prometheus Biosciences (RXDX)?

普羅米修斯生物科學公司(RXDX)的最新分析師評級是多少？

The latest analyst rating for Prometheus Biosciences (NASDAQ: RXDX) was provided by Goldman Sachs, and Prometheus Biosciences maintained their buy rating.

普羅米修斯生物科學公司(納斯達克代碼：RXDX)的最新分析師評級由高盛提供，普羅米修斯生物科學公司維持其買入評級。

When is the next analyst rating going to be posted or updated for Prometheus Biosciences (RXDX)?

普羅米修斯生物科學公司(RXDX)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prometheus Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prometheus Biosciences was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.

分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公開財務報表，與普羅米修斯生物科學公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。普羅米修斯生物科學公司的上一次評級是在2023年1月31日提交的，所以你應該預計下一次評級將在2024年1月31日左右的某個時候公佈。

Is the Analyst Rating Prometheus Biosciences (RXDX) correct?

分析師對普羅米修斯生物科學公司(RXDX)的評級正確嗎？

While ratings are subjective and will change, the latest Prometheus Biosciences (RXDX) rating was a maintained with a price target of $117.00 to $144.00. The current price Prometheus Biosciences (RXDX) is trading at is $114.77, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的普羅米修斯生物科學公司(Prometheus Biosciences)的評級保持不變，目標價在117.00美元至144.00美元之間。普羅米修斯生物科學公司目前的交易價格為114.77美元，超出了分析師的預測範圍。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論